Objective:To compare the contents of notoginsenoside R1 , ginsenoside Rg1 and ginsenoside Rb1 between Notoginseng Radix et Rhizoma and its formula granules. Methods:An HPLC method was used with a SunFire C18 column (250mm × 4. 6 mm, 5μm),the flow rate was 1. 0 ml·min-1, the detection wavelength was set at 203 nm, and the column temperature was at 30 ℃. The mobile phase was acetonitrile( A)-water( B) with gradient elution. An HPLC was used to determine the contents of the three ingredi-ents between Notoginseng Radix et Rhizoma and its formula granules, and compare the differences. Results: The total content of the three ingredients in Notoginseng Radix et Rhizoma and its formula granules was 9. 214% and 8. 646%, respectively. The total content of the three ingredients was equivalent and the daily amount of the major components in the commercial formula granules was equivalent with that in the decoction of Notoginseng Radix et Rhizoma. Conclusion:The production process of the original formula granules is re-liable, and the quality of formula granules of Notoginseng Radix et Rhizoma is stable.

Objective To compare the contents of liquiritin and glycyrrhizic acid between Glycyrrhizae Radix et Rhizoma decoction pieces and its formula granules.Methods HPLC method was used with Waters Atlantis T3 column (4.6 mm × 150 mm, 3μm), flow rate of 0.8 mL/min, detection wavelength of 237 nm, and column temperature at 30℃. The mobile phase was acetonitrile-0.1% phosphoric acid solution gradient elution system. The contents of liquiritin and glycyrrhizic acid of Glycyrrhizae Radix et Rhizoma decoction pieces and its formula granules were determined and compared.Results The contents of liquiritin and glycyrrhizic acid in formula granules were less than that in the decoction pieces of Glycyrrhizae Radix et Rhizoma, which was not in conformity with marked concentration multiple.Conclusion The contents of liquiritin and glycyrrhizic acid in formula granules is greatly different with Glycyrrhizae Radix et Rhizoma decoction pieces. The production process of the formula granules needs to be improved.

Objective:To establish the HPLC fingerprints of chemical constituents in Forsytiae suspensa Fructus from Shiyan dis-trict to provide scientific evidence for the quality control of Forsytiae suspensa Fructus. Methods: HPLC was performed on a Waters SunFire C18 (250 mm × 4. 6 mm, 5 μm) column and a Diamonsil C18 guard column, and the mobile phase consisted of acetonitrile-0. 4% acetic acid solution with gradient elution. The flow rate was 1 ml·min-1 , the detection wavelength was 277 nm, and the col-umn temperature was 30℃. Results:There were 14 common peaks in the HPLC fingerprints of chemical constituents in 12 batches of Forsytiae suspensa Fructus from Shiyan. The 14 characteristic peaks of Forsytiae suspensa Fructus from different habitats were under clustering analysis, and the similarity showed little difference. The contents of forsythoside A and forsythin exhibited significant differ-ence in the samples. Conclusion:The HPLC fingerprint method is simple, rapid and feasible in the quality control of Forsytiae suspen-sa Fructus.

Objective To compare the contents of forsythoside A and forsythin in Fructus Forsythia and its dispensing granule. Methods HPLC-gradient elution method was used with SunFire C18 column (4.6 mm×250 mm, 5μm), mobile phase A of acetonitrile and B of acetic acid, flow rate of 1.0 mL/min, detection wavelength of 277 nm, and column temperature at 30 ℃. HPLC was used to determine the contents of forsythoside A and forsythin in Fructus Forsythia and its dispensing granule, and compare the difference between the two contents. Results The content of forsythoside A in dispensing granule was less than that of raw material of Fructus Forsythia, and the concentration of the major components in the commercial Lianqiao Granule were not equivalent to that in the decoction of Fructus Forsythia. The content of forsythin in dispensing granule was equivalent with that of raw material of Fructus Forsythia. Conclusion The original formula granule production process needs to be improved, and the standardized criteria for the quality control and reasonable quality standard of granule should be established.

Objective: To study the dynamic changes of type Th22 cell immunological response during atherosclerosis process in experimental mice in order to provide a new theoretical basis for atherosclerosis therapy. Methods: 8 weeks C57BL/6J mice were divided into 2 groups: Experiment group,n=24 ApoE-/- mice and Control group, n=24 normal mice. All animals received high fat diet and the following indexes were compared between 2 groups at 0, 4, 8, 12 weeks after treatment: aortic atherosclerotic lesions were deifned by Oil red O staining, dynamic changes of Th22 cells in spleen were measured by lfow cytometry, mRNA expressions of interleukin-22 (IL-22), IL-22R1, AhR and T-bet in aorta were examined by RT-PCR, blood levels of IL-22 was detected by ELISA. Results: Compared with Control group, Experiment group had the increased area of aortic atherosclerosis (the ratio of plaque area/lumen area) and Th22 cell (CD4+ IL-22+/CD4+T cell) amount, elevated mRNA expressions of IL-22, IL-22R1, AHR, T-bet in aorta and higher blood levels of IL-22 at all time points, the differences between each time point (except 0 week) had the statistic meaning,P<0.05. In Experiment group, the differences between 2 adjacent time points, for the area of aortic atherosclerosis and mRNA expressions of AHR, T-bet: 4 weeks vs 0 week, 8 weeks vs 4 weeks, 12 weeks vs 8 weeks all had statistic meaning; for Th22 cell amount: 4 weeks vs 0 week, 8 weeks vs 4 weeks had statistic meaning and 12 weeks vs 8 weeks had no real distinction; for mRNA expressions of IL-22, IL-22R1 and blood levels of IL-22: 4 weeks vs 0 week had statistic meaning and 8 weeks vs 4 weeks, 12 weeks vs 8 weeks had no real distinctions. Conclusion: Hyperactive immunological response of Th22 cells might be involved in atherosclerosis process, the relevant mechanism should be further studied.

Objective To establish a specific HPLC method for simultaneous determination of three components ( baicalin, linarin and rhein) in Cuochuang Xiaoyan lotion. Methods The three components in Cuochuang Xiaoyan lotion were assayed by HPLC gradient elution method.The assay was performed with Waters Xterra MS C18(4.6 mm×250 mm,5 μm) column, with acetonitrile (A) and 0.2% phosphoric acid solution (B) as mobile phase in gradient elution.The flow rate was 1.0 mL·min-1.The detection wave length was 277 nm and column temperature was 30 ℃. Results Three components were completely separated from the adjacent peaks and a good linear relationship between each sample concentration and integral area was obtained.The linear equations were as follows:Ybaicalin=9.208X-0.0994(R2=0.9999, 83.97-839.70 μg·mL-1);Ylinarin=3.0628X-0.0038 ( R2 = 0. 9999, 34. 75-347. 49 μg · mL-1 );Yrhein = 1. 0225X-0. 0286 ( R2 = 0. 9998, 63. 20-632.00 μg·mL-1 ) . Conclusion The HPLC method is simple, accurate and reproducible, which is effective in controlling the quality of Cuochuang Xiaoyan lotion.

2019 novel coronavirus(2019-nCoV) outbreak is one of the public health emergency of international concern.Since the 2019-nCoV outbreak, China has been adopting strict prevention and control measures, and has achieved remarkable results in the initial stage of prevention and control.However, some imported cases and sporadic regional cases have been found, and even short-term regional epidemics have occurred, indicating that the preventing and control against the epidemic remains grim.With the change of the incidence proportion and the number of cases in children under 18 years old, some new special symptoms and complications have appeared in children patients.In addition, with the occurrence of virus mutation, it has not only attracted attention from all parties, but also proposed a new topic for the prevention and treatment of 2019-nCoV infection in children of China.Based on the second edition, the present consensus further summarizes the clinical characteristics and experience of children′s cases, and puts forward recommendations on the diagnostic criteria, laboratory examination, treatment, prevention and control of children′s cases for providing reference for further guidance of treatment of 2019-nCoV infection in children.

At present, severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)infection is still rampant worldwide.As of September 10, 2021, there were about 222 million confirmed cases of corona virus disease 2019(COVID-19)and more than 4.6 million deaths worldwide.With the development of COVID-19 vaccines and the gradual vaccination worldwide, the increasing number of cases in children and unvaccinated young people has drawn attention.According to World Health Organization surveillance data, the proportion of COVID-19 infection cases in children gradually increased, and the proportion of cases in the age groups of under 5 years and 5-14 years increased from 1.0% and 2.5% in January 2020 to 2.0% and 8.7% in July 2021, respectively.At present, billions of adults have been vaccinated with various COVID-19 vaccines worldwide, and their protective effects including reducing infection and transmission, reducing severe disease and hospitalization, and reducing death, as well as high safety have been confirmed.Canada, the United States, Europe and other countries have approved the emergency COVID-19 vaccination in children and adolescents aged 12 to 17 years, and China has also approved the phased vaccination of COVID-19 vaccination in children and adolescents aged 3 to 17 years. For smooth advancement and implementation of COVID-19 vaccination in children, academic institutions, including National Clinical Research Center for Respiratory Diseases, National Center for Children′s Health, and The Society of Pediatrics, Chinese Medical Association organized relevant experts to reach this consensus on COVID-19 vaccination in children.

Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)infection is still worldwide.As a vulnerable group, severe and dead pediatric cases are also reported.Under this severe epidemic situation, children should be well protected.With the widespread vaccination of SARS-CoV-2 vaccine in adults, the infection rate have decreased.Therefore, SARS-CoV-2 vaccine inoculation for children groups step by step is of great significance to the protection of children and the prevention and control of corona virus disease 2019(COVID-19) as a whole.But the safety of children vaccinated with SARS-CoV-2 vaccine is a main concern of parents.Therefore, in order to ensure the safety of vaccination and the implementation of vaccination work, National Clinical Research Center for Respiratory Diseases, National Center for Children′s Health and the Society of Pediatrics, Chinese Medical Association organized experts to interpret the main issue of parents about SARS-CoV-2 vaccine for children, in order to answer the doubts of parents.

China has classified the Corona Virus Disease 2019(COVID-19) as a statutory category B infectious disease and managed it according to Category B since January 8, 2023.In view that Omicron variant is currently the main epidemic strain in China, in order to guide the treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection in children with the times, refer to the Diagnosis and Treatment Protocol for Novel Coronavirus Infection (Trial 10 th Edition), Expert Consensus on Diagnosis, Treatment and Prevention of Novel Coronavirus Infection in Children (Fourth Edition) and the Diagnosis and Treatment Strategy for Pediatric Related Viral Infections.The Expert Consensus on the Diagnosis, Treatment and Prevention of Novel Coronavirus Infection in Children (Fifth Edition) has been formulated and updated accordingly on related etiology, epidemiology, pathogenic mechanism, clinical manifestations, auxiliary examination, diagnosis and treatment, and added key points for the treatment of COVID-19 related encephalopathy, fulminating myocarditis and other serious complications for clinical reference.